Fu L Luan1, Linda J Stuckey, Akinlolu O Ojo. 1. Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. fluan@med.umich.edu
Abstract
BACKGROUND: Abnormal glucose metabolism (AGM) and metabolic syndrome (MS) are individually associated with a poor cardiovascular outcome in kidney transplant recipients. We prospectively studied the relationship between AGM and MS in non-diabetic kidney transplant recipients early after transplantation. METHODS: A total of 203 de novo kidney transplant recipients underwent standard 2-hr glucose tolerance test 10 weeks after transplantation. Demographic and clinical characteristics were collected. AGM was defined as impaired fasting glucose, impaired glucose tolerance, and new onset diabetes after transplant according to the WHO criteria, and MS was defined according to the National Cholesterol Education Expert Panel criteria. RESULTS: Overall, 97 patients (47.8%) met the diagnosis of AGM and 98 patients (48.3%) met the criteria of MS. AGM and MS are highly associated (chi, P<0.001). Fasting plasma glucose levels before the transplant are independent predictors common for AGM and MS. Age predicts AGM with and without MS, whereas body mass index before transplant predicts MS. Patients with impaired glucose tolerance and new-onset diabetes after transplant displayed significant worsening of their fasting plasma glucose levels during the 10-week observational period. MS and the components of MS, but not AGM, were associated with reduced transplant renal function (P=0.002). CONCLUSION: The early screening of AGM and MS should be emphasized, and the role of early therapeutic interventions aimed at both conditions explored. The long-term follow-up of these patients will yield more insight on the significance of such findings.
BACKGROUND:Abnormal glucose metabolism (AGM) and metabolic syndrome (MS) are individually associated with a poor cardiovascular outcome in kidney transplant recipients. We prospectively studied the relationship between AGM and MS in non-diabetic kidney transplant recipients early after transplantation. METHODS: A total of 203 de novo kidney transplant recipients underwent standard 2-hr glucose tolerance test 10 weeks after transplantation. Demographic and clinical characteristics were collected. AGM was defined as impaired fasting glucose, impaired glucose tolerance, and new onset diabetes after transplant according to the WHO criteria, and MS was defined according to the National Cholesterol Education Expert Panel criteria. RESULTS: Overall, 97 patients (47.8%) met the diagnosis of AGM and 98 patients (48.3%) met the criteria of MS. AGM and MS are highly associated (chi, P<0.001). Fasting plasma glucose levels before the transplant are independent predictors common for AGM and MS. Age predicts AGM with and without MS, whereas body mass index before transplant predicts MS. Patients with impaired glucose tolerance and new-onset diabetes after transplant displayed significant worsening of their fasting plasma glucose levels during the 10-week observational period. MS and the components of MS, but not AGM, were associated with reduced transplant renal function (P=0.002). CONCLUSION: The early screening of AGM and MS should be emphasized, and the role of early therapeutic interventions aimed at both conditions explored. The long-term follow-up of these patients will yield more insight on the significance of such findings.
Authors: Fernando G Cosio; Yogish Kudva; Marije van der Velde; Timothy S Larson; Stephen C Textor; Matthew D Griffin; Mark D Stegall Journal: Kidney Int Date: 2005-06 Impact factor: 10.612
Authors: Lorraine C Racusen; Robert B Colvin; Kim Solez; Michael J Mihatsch; Philip F Halloran; Patricia M Campbell; Michael J Cecka; Jean-Pierre Cosyns; Anthony J Demetris; Michael C Fishbein; Agnes Fogo; Peter Furness; Ian W Gibson; Denis Glotz; Pekka Hayry; Lawrence Hunsickern; Michael Kashgarian; Ronald Kerman; Alex J Magil; Robert Montgomery; Kunio Morozumi; Volker Nickeleit; Parmjeet Randhawa; Heinz Regele; Daniel Seron; Surya Seshan; Stale Sund; Kiril Trpkov Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086
Authors: Manfred Hecking; Michael Haidinger; Dominik Döller; Johannes Werzowa; Andrea Tura; Jinyao Zhang; Hilal Tekoglu; Johannes Pleiner; Thomas Wrba; Susanne Rasoul-Rockenschaub; Ferdinand Mühlbacher; Sabine Schmaldienst; Wilfred Druml; Walter H Hörl; Michael Krebs; Michael Wolzt; Giovanni Pacini; Friedrich K Port; Marcus D Säemann Journal: J Am Soc Nephrol Date: 2012-02-16 Impact factor: 10.121
Authors: Maria P Martinez Cantarin; Scott W Keith; Zhao Lin; Cataldo Doria; Adam M Frank; Warren R Maley; Carlo Ramirez; Costas D Lallas; Ashesh Shah; Scott A Waldman; Bonita Falkner Journal: Cardiorenal Med Date: 2016-05-18 Impact factor: 2.041
Authors: Manfred Hecking; Alexander Kainz; Johannes Werzowa; Michael Haidinger; Dominik Döller; Andrea Tura; Angelo Karaboyas; Walter H Hörl; Michael Wolzt; Adnan Sharif; Michael Roden; Ermanno Moro; Giovanni Pacini; Friedrich K Port; Marcus D Säemann Journal: Diabetes Care Date: 2013-05-08 Impact factor: 19.112
Authors: Claudia Sommerer; Oliver Witzke; Frank Lehner; Wolfgang Arns; Petra Reinke; Ute Eisenberger; Bruno Vogt; Katharina Heller; Johannes Jacobi; Markus Guba; Rolf Stahl; Ingeborg A Hauser; Volker Kliem; Rudolf P Wüthrich; Anja Mühlfeld; Barbara Suwelack; Michael Duerr; Eva-Maria Paulus; Martin Zeier; Martina Porstner; Klemens Budde Journal: BMC Nephrol Date: 2018-09-19 Impact factor: 2.388
Authors: Elisabeth Schwaiger; Simon Krenn; Amelie Kurnikowski; Leon Bergfeld; María José Pérez-Sáez; Alexander Frey; David Topitz; Michael Bergmann; Sebastian Hödlmoser; Friederike Bachmann; Fabian Halleck; Susanne Kron; Hildegard Hafner-Giessauf; Kathrin Eller; Alexander R Rosenkranz; Marta Crespo; Anna Faura; Andrea Tura; Peter X K Song; Friedrich K Port; Julio Pascual; Klemens Budde; Robin Ristl; Johannes Werzowa; Manfred Hecking Journal: J Am Soc Nephrol Date: 2021-08 Impact factor: 14.978